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Background and aim
PIK3CA gene mutations are a source of
heterogeneity in HER2+ BC.
We explored the frequency and
prognostic impact of PIK3CA mutations in
the randomized adjuvant ShortHER trial.
Methods
The ShortHER trial randomized 1254
patients with HER2+ early BC to 9 weeks
or 1 year of adjuvant trastuzumab
combined with chemotherapy. Non-
inferiority of the short arm was not
demonstrated with the frequentist
approach1.
PIK3CA hot-spot mutations in exon 9
(E542K, E545K-A-G, Q546E-K) and exon
20 (M1043I, H1047R-L-Y, G1049R-S) were
analysed by using Pyrosequencing
method on DNA extracted from
centralized FFPE tumor samples.
Intrinsic molecular subtypes from tumor
samples were determined using PAM50 
from nCounter.
Results
Characteristics PIK3CA mut
N (%)
PIK3CA wt
N (%)
TOT
N (%)
P
Total 174 (22%) 629 (78%) 803 (100%) -
Age (y)
median (Q1-Q3)
57 (50-64) 56 (48-64) 56 (48-64) 0.169
Postmenopausal 49 (28) 227 (36) 276 (34)
Premenopausal 125 (72) 401 (64) 526 (66) 0.050
AJCC Stage I 70 (40) 259 (41) 329 (41)
AJCC Stage II 77 (44) 277 (44) 354 (44)
AJCC Stage III 27 (16) 91 (15) 118 (15) 0.936
N0
N1-N2
N3
85 (49)
61 (35)
28 (16)
343 (55)
191 (30)
95 (15)
428 (53)
252 (31)
123 (15) 0.393
Hormone rec Neg 41 (24) 195 (31) 236 (29)
Hormone rec Pos 133 (76) 434 (69) 567 (71) 0.057
Grade 1-2 54 (31) 172 (28) 226 (28)
Grade 3 118 (69) 448 (72) 566 (72) 0.348
TILs
Median (Q1-Q3)
5 (1-15) 5 (1-15) 5 (1-15) 0.637
PAM50 LumA
PAM50 LumB
PAM50 HER2-E
PAM50 Basal
PAM50 Normal
22 (24)
8 (9)
49 (53)
2 (2)
11 (12)
64 (19)
34 (10)
183 (54)
25 (7)
35 (10)
86 (20)
42 (10)
232 (54)
27 (6)
46 (11)
0.358
Conclusions
Within the HER2-enriched molecular subtype, PIK3CA mutated patients
showed better DFS as compared to PIK3CA wild-type patients.
These results highlight the need to integrate multiple biomarkers in order to
dissect the heterogeneity of HER2-positive breast cancer.
A PIK3CA mutation was found in 22% out of 803 patients. 
Table 1 shows the association between PIK3CA mutation and 
clinicopathological characteristics.
PIK3CA mutation had no impact
on DFS in the whole study
cohort (Figure 1) and in
subgroups defined by hormone
receptor status (HR=0.87, 95%CI
0.39-1.95 for hormone receptor
negative and HR=0.84, 95%CI
0.52-1.36 for hormone receptor
positive).
PIK3CA mutation was associated
with better DFS as compared to
PIK3CA wild-type in the HER2-
enriched intrinsic subtype
(Figure 2). No prognostic impact
in non-HER2-enriched patients
was observed (HR=1.29, 95%CI
0.57-2.89).
Figure 1. KM DFS curves by PIK3CA
status in the whole study cohort.
Figure 2. KM DFS curves by PIK3CA
status in the HER2-enriched subtype.
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